Larvol Sigma is the first and only free clinical trial and pipeline intelligence platform. In addition to enabling faster, easier access to ClinicalTrials.gov and EudraCT, the platform also provides advanced analytics tailored to meet the specific needs of the pharmaceutical and biotech industries. With a database containing over 5,000 drugs as well as more than 150,000 individual drug trials across all major indications, Larvol Sigma is a comprehensive resource for investigators, researchers and industry professionals. The platform is available at www.larvolsigma.com.
"Our goal with Larvol Sigma has been to fill the gaps for small-to-midsize biotech firms," commented company President Bruno Larvol. "We understand that sometimes a subscription service is outside the scope of a particular initiative. With this platform, users can quickly gain a broader understanding of the market and find relevant news, sorted by specific diseases, companies, products, mechanisms of action, and investigators – with the option of upgrading to a curated subscription should they need more in-depth coverage.”
Representatives from The Larvol Group will be available at the conference, which takes places September 9-10th. Interested parties are encouraged to stop by our booth (#16) in the exhibit hall and meet with Executive Vice President Laura Farmer and Engagement Manager Joanne Francis. If you are interested in scheduling a meeting with The Larvol Group during this year’s Pharma CI Conference, please contact Jacob Brissee at Jacob.Brissee@
About The Larvol Group, LLC:
Founded in 2004, The Larvol Group, LLC provides innovative solutions to the pharmaceutical and healthcare industries. Pharmaceutical solutions include competitive intelligence tracking, medical writing, and other support services. Healthcare solutions include medical coding, chart review, HEOR studies, and data analysis services. Our team of over 100 professionals has expertise in all major therapeutic areas with a special focus on oncology, inflammation, cardiovascular disease, and CNS. Our clients include Fortune 500 companies as well as small and midsize enterprises.